Global Infective Endocarditis Treatment Market Growth (Status and Outlook) 2026-2032

September 2026 | 93 pages | ID: G88B6BD111FFEN
LP Information

Abstracts

The global Infective Endocarditis Treatment market size is predicted to grow from US$ 1282 million in 2025 to US$ 1877 million in 2032; it is expected to grow at a CAGR of 5.7% from 2026 to 2032.

Infective endocarditis is an infection of the inner lining of the heart. It is a serious infection that is frequently fatal, and cardiac surgery is often required. Antibiotics are medicines that treat infections and are the cornerstone of treatment for infective endocarditis.Infective Endocarditis is treated with long-term courses of intravenous antibiotics or antifungals.

The global infective endocarditis treatment market refers to the market for products and therapies used in the treatment of infective endocarditis (IE). IE is a serious infection of the endocardium, which is the inner lining of the heart valves and chambers. It is typically caused by bacteria, but can also be caused by fungi or other microorganisms.

Infective endocarditis can result in severe complications, including heart valve damage, heart failure, and systemic embolisms. Prompt and effective treatment is essential to manage the infection, control symptoms, and prevent complications.

The market for infective endocarditis treatment is driven by several factors:

Increasing incidence of infective endocarditis: The prevalence of infective endocarditis has been on the rise in recent years, particularly among individuals with risk factors such as intravenous drug use, prosthetic heart valves, or a history of cardiac surgery. This has created a growing patient population requiring treatment.

Advances in diagnostic techniques: Improvements in diagnostic tools, such as blood culture systems, imaging technologies (echocardiography), and laboratory tests, facilitate the early and accurate diagnosis of infective endocarditis. Early detection enables timely initiation of treatment and improves patient outcomes.

Developing antimicrobial resistance: The emergence of antimicrobial resistance poses challenges in treating infective endocarditis. New therapies and combination antibiotic regimens are constantly being researched and developed to effectively combat drug-resistant microorganisms, driving the demand for innovative treatment options.

Technological advancements in surgical interventions: In cases where medical management alone is insufficient, surgical interventions like valve replacement or repair may be necessary. Technological advancements in surgical techniques, such as minimally invasive procedures and the use of bioprosthetic valves, have improved patient outcomes and expanded the treatment options available.

The global infective endocarditis treatment market includes various stakeholders, including pharmaceutical companies, medical device manufacturers, hospitals, and healthcare providers. Companies in this market develop and provide antibiotics, antifungal agents, surgical instruments, prosthetic valves, and supportive therapies for infective endocarditis treatment.

Additionally, research and development efforts are focused on discovering new therapeutic agents, optimizing treatment regimens, and exploring alternative treatment strategies. Collaboration between academia, pharmaceutical companies, and healthcare providers plays a vital role in driving innovation in the field.

LPI (LP Information)' newest research report, the “Infective Endocarditis Treatment Industry Forecast” looks at past sales and reviews total world Infective Endocarditis Treatment sales in 2025, providing a comprehensive analysis by region and market sector of projected Infective Endocarditis Treatment sales for 2026 through 2032. With Infective Endocarditis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Infective Endocarditis Treatment industry.

This Insight Report provides a comprehensive analysis of the global Infective Endocarditis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Infective Endocarditis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Infective Endocarditis Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Infective Endocarditis Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Infective Endocarditis Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Infective Endocarditis Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Antibiotic Therapy
• Recombinant Enzyme Therapy

Segmentation by Application:

• Acute Endocarditis
• Subacute Endocarditis

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Pfizer, Inc.
• Novartis AG
• Eli Lilly and Company
• Merck & Co., Inc.
• Allergan
• Roche Holding AG
• Teva Pharmaceutical
• Mylan N.V.
• Fresenius Kabi AG
• Galderma S.A.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Infective Endocarditis Treatment Market Size (2021-2032)
  2.1.2 Infective Endocarditis Treatment Market Size CAGR by Region (2021 VS 2025 VS 2032)
  2.1.3 World Current & Future Analysis for Infective Endocarditis Treatment by Country/Region (2021, 2025 & 2032)
2.2 Infective Endocarditis Treatment Segment by Type
  2.2.1 Antibiotic Therapy
  2.2.2 Recombinant Enzyme Therapy
  2.2.3 Infective Endocarditis Treatment Market Size by Type
    2.2.3.1 Infective Endocarditis Treatment Market Size CAGR by Type (2021 VS 2025 VS 2032)
    2.2.3.2 Global Infective Endocarditis Treatment Market Size Market Share by Type (2021-2026)
2.3 Infective Endocarditis Treatment Segment by Application
  2.3.1 Acute Endocarditis
  2.3.2 Subacute Endocarditis
  2.3.3 Infective Endocarditis Treatment Market Size by Application
    2.3.3.1 Infective Endocarditis Treatment Market Size CAGR by Application (2021 VS 2025 VS 2032)
    2.3.3.2 Global Infective Endocarditis Treatment Market Size Market Share by Application (2021-2026)

3 INFECTIVE ENDOCARDITIS TREATMENT MARKET SIZE BY PLAYER

3.1 Infective Endocarditis Treatment Market Size Market Share by Player
  3.1.1 Global Infective Endocarditis Treatment Revenue by Player (2021-2026)
  3.1.2 Global Infective Endocarditis Treatment Revenue Market Share by Player (2021-2026)
3.2 Global Infective Endocarditis Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 INFECTIVE ENDOCARDITIS TREATMENT BY REGION

4.1 Infective Endocarditis Treatment Market Size by Region (2021-2026)
4.2 Global Infective Endocarditis Treatment Annual Revenue by Country/Region (2021-2026)
4.3 Americas Infective Endocarditis Treatment Market Size Growth (2021-2026)
4.4 APAC Infective Endocarditis Treatment Market Size Growth (2021-2026)
4.5 Europe Infective Endocarditis Treatment Market Size Growth (2021-2026)
4.6 Middle East & Africa Infective Endocarditis Treatment Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Infective Endocarditis Treatment Market Size by Country (2021-2026)
5.2 Americas Infective Endocarditis Treatment Market Size by Type (2021-2026)
5.3 Americas Infective Endocarditis Treatment Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Infective Endocarditis Treatment Market Size by Region (2021-2026)
6.2 APAC Infective Endocarditis Treatment Market Size by Type (2021-2026)
6.3 APAC Infective Endocarditis Treatment Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Infective Endocarditis Treatment Market Size by Country (2021-2026)
7.2 Europe Infective Endocarditis Treatment Market Size by Type (2021-2026)
7.3 Europe Infective Endocarditis Treatment Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Infective Endocarditis Treatment by Region (2021-2026)
8.2 Middle East & Africa Infective Endocarditis Treatment Market Size by Type (2021-2026)
8.3 Middle East & Africa Infective Endocarditis Treatment Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL INFECTIVE ENDOCARDITIS TREATMENT MARKET FORECAST

10.1 Global Infective Endocarditis Treatment Forecast by Region (2027-2032)
  10.1.1 Global Infective Endocarditis Treatment Forecast by Region (2027-2032)
  10.1.2 Americas Infective Endocarditis Treatment Forecast
  10.1.3 APAC Infective Endocarditis Treatment Forecast
  10.1.4 Europe Infective Endocarditis Treatment Forecast
  10.1.5 Middle East & Africa Infective Endocarditis Treatment Forecast
10.2 Americas Infective Endocarditis Treatment Forecast by Country (2027-2032)
  10.2.1 United States Market Infective Endocarditis Treatment Forecast
  10.2.2 Canada Market Infective Endocarditis Treatment Forecast
  10.2.3 Mexico Market Infective Endocarditis Treatment Forecast
  10.2.4 Brazil Market Infective Endocarditis Treatment Forecast
10.3 APAC Infective Endocarditis Treatment Forecast by Region (2027-2032)
  10.3.1 China Infective Endocarditis Treatment Market Forecast
  10.3.2 Japan Market Infective Endocarditis Treatment Forecast
  10.3.3 Korea Market Infective Endocarditis Treatment Forecast
  10.3.4 Southeast Asia Market Infective Endocarditis Treatment Forecast
  10.3.5 India Market Infective Endocarditis Treatment Forecast
  10.3.6 Australia Market Infective Endocarditis Treatment Forecast
10.4 Europe Infective Endocarditis Treatment Forecast by Country (2027-2032)
  10.4.1 Germany Market Infective Endocarditis Treatment Forecast
  10.4.2 France Market Infective Endocarditis Treatment Forecast
  10.4.3 UK Market Infective Endocarditis Treatment Forecast
  10.4.4 Italy Market Infective Endocarditis Treatment Forecast
  10.4.5 Russia Market Infective Endocarditis Treatment Forecast
10.5 Middle East & Africa Infective Endocarditis Treatment Forecast by Region (2027-2032)
  10.5.1 Egypt Market Infective Endocarditis Treatment Forecast
  10.5.2 South Africa Market Infective Endocarditis Treatment Forecast
  10.5.3 Israel Market Infective Endocarditis Treatment Forecast
  10.5.4 Turkey Market Infective Endocarditis Treatment Forecast
10.6 Global Infective Endocarditis Treatment Forecast by Type (2027-2032)
10.7 Global Infective Endocarditis Treatment Forecast by Application (2027-2032)
  10.7.1 GCC Countries Market Infective Endocarditis Treatment Forecast

11 KEY PLAYERS ANALYSIS

11.1 Pfizer, Inc.
  11.1.1 Pfizer, Inc. Company Information
  11.1.2 Pfizer, Inc. Infective Endocarditis Treatment Product Offered
  11.1.3 Pfizer, Inc. Infective Endocarditis Treatment Revenue, Gross Margin and Market Share (2021-2026)
  11.1.4 Pfizer, Inc. Main Business Overview
  11.1.5 Pfizer, Inc. Latest Developments
11.2 Novartis AG
  11.2.1 Novartis AG Company Information
  11.2.2 Novartis AG Infective Endocarditis Treatment Product Offered
  11.2.3 Novartis AG Infective Endocarditis Treatment Revenue, Gross Margin and Market Share (2021-2026)
  11.2.4 Novartis AG Main Business Overview
  11.2.5 Novartis AG Latest Developments
11.3 Eli Lilly and Company
  11.3.1 Eli Lilly and Company Company Information
  11.3.2 Eli Lilly and Company Infective Endocarditis Treatment Product Offered
  11.3.3 Eli Lilly and Company Infective Endocarditis Treatment Revenue, Gross Margin and Market Share (2021-2026)
  11.3.4 Eli Lilly and Company Main Business Overview
  11.3.5 Eli Lilly and Company Latest Developments
11.4 Merck & Co., Inc.
  11.4.1 Merck & Co., Inc. Company Information
  11.4.2 Merck & Co., Inc. Infective Endocarditis Treatment Product Offered
  11.4.3 Merck & Co., Inc. Infective Endocarditis Treatment Revenue, Gross Margin and Market Share (2021-2026)
  11.4.4 Merck & Co., Inc. Main Business Overview
  11.4.5 Merck & Co., Inc. Latest Developments
11.5 Allergan
  11.5.1 Allergan Company Information
  11.5.2 Allergan Infective Endocarditis Treatment Product Offered
  11.5.3 Allergan Infective Endocarditis Treatment Revenue, Gross Margin and Market Share (2021-2026)
  11.5.4 Allergan Main Business Overview
  11.5.5 Allergan Latest Developments
11.6 Roche Holding AG
  11.6.1 Roche Holding AG Company Information
  11.6.2 Roche Holding AG Infective Endocarditis Treatment Product Offered
  11.6.3 Roche Holding AG Infective Endocarditis Treatment Revenue, Gross Margin and Market Share (2021-2026)
  11.6.4 Roche Holding AG Main Business Overview
  11.6.5 Roche Holding AG Latest Developments
11.7 Teva Pharmaceutical
  11.7.1 Teva Pharmaceutical Company Information
  11.7.2 Teva Pharmaceutical Infective Endocarditis Treatment Product Offered
  11.7.3 Teva Pharmaceutical Infective Endocarditis Treatment Revenue, Gross Margin and Market Share (2021-2026)
  11.7.4 Teva Pharmaceutical Main Business Overview
  11.7.5 Teva Pharmaceutical Latest Developments
11.8 Mylan N.V.
  11.8.1 Mylan N.V. Company Information
  11.8.2 Mylan N.V. Infective Endocarditis Treatment Product Offered
  11.8.3 Mylan N.V. Infective Endocarditis Treatment Revenue, Gross Margin and Market Share (2021-2026)
  11.8.4 Mylan N.V. Main Business Overview
  11.8.5 Mylan N.V. Latest Developments
11.9 Fresenius Kabi AG
  11.9.1 Fresenius Kabi AG Company Information
  11.9.2 Fresenius Kabi AG Infective Endocarditis Treatment Product Offered
  11.9.3 Fresenius Kabi AG Infective Endocarditis Treatment Revenue, Gross Margin and Market Share (2021-2026)
  11.9.4 Fresenius Kabi AG Main Business Overview
  11.9.5 Fresenius Kabi AG Latest Developments
11.10 Galderma S.A.
  11.10.1 Galderma S.A. Company Information
  11.10.2 Galderma S.A. Infective Endocarditis Treatment Product Offered
  11.10.3 Galderma S.A. Infective Endocarditis Treatment Revenue, Gross Margin and Market Share (2021-2026)
  11.10.4 Galderma S.A. Main Business Overview
  11.10.5 Galderma S.A. Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Infective Endocarditis Treatment Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Infective Endocarditis Treatment Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antibiotic Therapy
Table 4. Major Players of Recombinant Enzyme Therapy
Table 5. Infective Endocarditis Treatment Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Infective Endocarditis Treatment Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Infective Endocarditis Treatment Market Size Market Share by Type (2021-2026)
Table 8. Infective Endocarditis Treatment Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Infective Endocarditis Treatment Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Infective Endocarditis Treatment Market Size Market Share by Application (2021-2026)
Table 11. Global Infective Endocarditis Treatment Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Infective Endocarditis Treatment Revenue Market Share by Player (2021-2026)
Table 13. Infective Endocarditis Treatment Key Players Head office and Products Offered
Table 14. Infective Endocarditis Treatment Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Infective Endocarditis Treatment Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Infective Endocarditis Treatment Market Size Market Share by Region (2021-2026)
Table 19. Global Infective Endocarditis Treatment Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Infective Endocarditis Treatment Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Infective Endocarditis Treatment Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Infective Endocarditis Treatment Market Size Market Share by Country (2021-2026)
Table 23. Americas Infective Endocarditis Treatment Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Infective Endocarditis Treatment Market Size Market Share by Type (2021-2026)
Table 25. Americas Infective Endocarditis Treatment Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Infective Endocarditis Treatment Market Size Market Share by Application (2021-2026)
Table 27. APAC Infective Endocarditis Treatment Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Infective Endocarditis Treatment Market Size Market Share by Region (2021-2026)
Table 29. APAC Infective Endocarditis Treatment Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Infective Endocarditis Treatment Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Infective Endocarditis Treatment Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Infective Endocarditis Treatment Market Size Market Share by Country (2021-2026)
Table 33. Europe Infective Endocarditis Treatment Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Infective Endocarditis Treatment Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Infective Endocarditis Treatment Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Infective Endocarditis Treatment Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Infective Endocarditis Treatment Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Infective Endocarditis Treatment
Table 39. Key Market Challenges & Risks of Infective Endocarditis Treatment
Table 40. Key Industry Trends of Infective Endocarditis Treatment
Table 41. Global Infective Endocarditis Treatment Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Infective Endocarditis Treatment Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Infective Endocarditis Treatment Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Infective Endocarditis Treatment Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Pfizer, Inc. Details, Company Type, Infective Endocarditis Treatment Area Served and Its Competitors
Table 46. Pfizer, Inc. Infective Endocarditis Treatment Product Offered
Table 47. Pfizer, Inc. Infective Endocarditis Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Pfizer, Inc. Main Business
Table 49. Pfizer, Inc. Latest Developments
Table 50. Novartis AG Details, Company Type, Infective Endocarditis Treatment Area Served and Its Competitors
Table 51. Novartis AG Infective Endocarditis Treatment Product Offered
Table 52. Novartis AG Infective Endocarditis Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Novartis AG Main Business
Table 54. Novartis AG Latest Developments
Table 55. Eli Lilly and Company Details, Company Type, Infective Endocarditis Treatment Area Served and Its Competitors
Table 56. Eli Lilly and Company Infective Endocarditis Treatment Product Offered
Table 57. Eli Lilly and Company Infective Endocarditis Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Eli Lilly and Company Main Business
Table 59. Eli Lilly and Company Latest Developments
Table 60. Merck & Co., Inc. Details, Company Type, Infective Endocarditis Treatment Area Served and Its Competitors
Table 61. Merck & Co., Inc. Infective Endocarditis Treatment Product Offered
Table 62. Merck & Co., Inc. Infective Endocarditis Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Merck & Co., Inc. Main Business
Table 64. Merck & Co., Inc. Latest Developments
Table 65. Allergan Details, Company Type, Infective Endocarditis Treatment Area Served and Its Competitors
Table 66. Allergan Infective Endocarditis Treatment Product Offered
Table 67. Allergan Infective Endocarditis Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Allergan Main Business
Table 69. Allergan Latest Developments
Table 70. Roche Holding AG Details, Company Type, Infective Endocarditis Treatment Area Served and Its Competitors
Table 71. Roche Holding AG Infective Endocarditis Treatment Product Offered
Table 72. Roche Holding AG Infective Endocarditis Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Roche Holding AG Main Business
Table 74. Roche Holding AG Latest Developments
Table 75. Teva Pharmaceutical Details, Company Type, Infective Endocarditis Treatment Area Served and Its Competitors
Table 76. Teva Pharmaceutical Infective Endocarditis Treatment Product Offered
Table 77. Teva Pharmaceutical Infective Endocarditis Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Teva Pharmaceutical Main Business
Table 79. Teva Pharmaceutical Latest Developments
Table 80. Mylan N.V. Details, Company Type, Infective Endocarditis Treatment Area Served and Its Competitors
Table 81. Mylan N.V. Infective Endocarditis Treatment Product Offered
Table 82. Mylan N.V. Infective Endocarditis Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Mylan N.V. Main Business
Table 84. Mylan N.V. Latest Developments
Table 85. Fresenius Kabi AG Details, Company Type, Infective Endocarditis Treatment Area Served and Its Competitors
Table 86. Fresenius Kabi AG Infective Endocarditis Treatment Product Offered
Table 87. Fresenius Kabi AG Infective Endocarditis Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Fresenius Kabi AG Main Business
Table 89. Fresenius Kabi AG Latest Developments
Table 90. Galderma S.A. Details, Company Type, Infective Endocarditis Treatment Area Served and Its Competitors
Table 91. Galderma S.A. Infective Endocarditis Treatment Product Offered
Table 92. Galderma S.A. Infective Endocarditis Treatment Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Galderma S.A. Main Business
Table 94. Galderma S.A. Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Infective Endocarditis Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Infective Endocarditis Treatment Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Infective Endocarditis Treatment Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Infective Endocarditis Treatment Sales Market Share by Country/Region (2025)
Figure 8. Infective Endocarditis Treatment Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Infective Endocarditis Treatment Market Size Market Share by Type in 2025
Figure 10. Infective Endocarditis Treatment in Acute Endocarditis
Figure 11. Global Infective Endocarditis Treatment Market: Acute Endocarditis (2021-2026) & ($ millions)
Figure 12. Infective Endocarditis Treatment in Subacute Endocarditis
Figure 13. Global Infective Endocarditis Treatment Market: Subacute Endocarditis (2021-2026) & ($ millions)
Figure 14. Global Infective Endocarditis Treatment Market Size Market Share by Application in 2025
Figure 15. Global Infective Endocarditis Treatment Revenue Market Share by Player in 2025
Figure 16. Global Infective Endocarditis Treatment Market Size Market Share by Region (2021-2026)
Figure 17. Americas Infective Endocarditis Treatment Market Size 2021-2026 ($ millions)
Figure 18. APAC Infective Endocarditis Treatment Market Size 2021-2026 ($ millions)
Figure 19. Europe Infective Endocarditis Treatment Market Size 2021-2026 ($ millions)
Figure 20. Middle East & Africa Infective Endocarditis Treatment Market Size 2021-2026 ($ millions)
Figure 21. Americas Infective Endocarditis Treatment Value Market Share by Country in 2025
Figure 22. United States Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 23. Canada Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 24. Mexico Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 25. Brazil Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 26. APAC Infective Endocarditis Treatment Market Size Market Share by Region in 2025
Figure 27. APAC Infective Endocarditis Treatment Market Size Market Share by Type (2021-2026)
Figure 28. APAC Infective Endocarditis Treatment Market Size Market Share by Application (2021-2026)
Figure 29. China Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 30. Japan Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 31. South Korea Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 32. Southeast Asia Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 33. India Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 34. Australia Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 35. Europe Infective Endocarditis Treatment Market Size Market Share by Country in 2025
Figure 36. Europe Infective Endocarditis Treatment Market Size Market Share by Type (2021-2026)
Figure 37. Europe Infective Endocarditis Treatment Market Size Market Share by Application (2021-2026)
Figure 38. Germany Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 39. France Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 40. UK Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 41. Italy Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 42. Russia Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 43. Middle East & Africa Infective Endocarditis Treatment Market Size Market Share by Region (2021-2026)
Figure 44. Middle East & Africa Infective Endocarditis Treatment Market Size Market Share by Type (2021-2026)
Figure 45. Middle East & Africa Infective Endocarditis Treatment Market Size Market Share by Application (2021-2026)
Figure 46. Egypt Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 47. South Africa Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 48. Israel Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 49. Turkey Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 50. GCC Countries Infective Endocarditis Treatment Market Size Growth 2021-2026 ($ millions)
Figure 51. Americas Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 52. APAC Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 53. Europe Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 54. Middle East & Africa Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 55. United States Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 56. Canada Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 57. Mexico Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 58. Brazil Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 59. China Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 60. Japan Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 61. Korea Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 62. Southeast Asia Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 63. India Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 64. Australia Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 65. Germany Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 66. France Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 67. UK Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 68. Italy Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 69. Russia Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 70. Egypt Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 71. South Africa Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 72. Israel Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 73. Turkey Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)
Figure 74. Global Infective Endocarditis Treatment Market Size Market Share Forecast by Type (2027-2032)
Figure 75. Global Infective Endocarditis Treatment Market Size Market Share Forecast by Application (2027-2032)
Figure 76. GCC Countries Infective Endocarditis Treatment Market Size 2027-2032 ($ millions)